12

 · worldwide. In June 2018, Biocon and Mylan became the first to receive approval for biosimilar Pegfilgrastim from the U.S. FDA, ahead of a pack of strong competitors who are also

  • Upload
    others

  • View
    0

  • Download
    0

Embed Size (px)

Citation preview

Page 1:  · worldwide. In June 2018, Biocon and Mylan became the first to receive approval for biosimilar Pegfilgrastim from the U.S. FDA, ahead of a pack of strong competitors who are also
Page 2:  · worldwide. In June 2018, Biocon and Mylan became the first to receive approval for biosimilar Pegfilgrastim from the U.S. FDA, ahead of a pack of strong competitors who are also
Page 3:  · worldwide. In June 2018, Biocon and Mylan became the first to receive approval for biosimilar Pegfilgrastim from the U.S. FDA, ahead of a pack of strong competitors who are also
Page 4:  · worldwide. In June 2018, Biocon and Mylan became the first to receive approval for biosimilar Pegfilgrastim from the U.S. FDA, ahead of a pack of strong competitors who are also
Page 5:  · worldwide. In June 2018, Biocon and Mylan became the first to receive approval for biosimilar Pegfilgrastim from the U.S. FDA, ahead of a pack of strong competitors who are also
Page 6:  · worldwide. In June 2018, Biocon and Mylan became the first to receive approval for biosimilar Pegfilgrastim from the U.S. FDA, ahead of a pack of strong competitors who are also
Page 7:  · worldwide. In June 2018, Biocon and Mylan became the first to receive approval for biosimilar Pegfilgrastim from the U.S. FDA, ahead of a pack of strong competitors who are also
Page 8:  · worldwide. In June 2018, Biocon and Mylan became the first to receive approval for biosimilar Pegfilgrastim from the U.S. FDA, ahead of a pack of strong competitors who are also
Page 9:  · worldwide. In June 2018, Biocon and Mylan became the first to receive approval for biosimilar Pegfilgrastim from the U.S. FDA, ahead of a pack of strong competitors who are also
Page 10:  · worldwide. In June 2018, Biocon and Mylan became the first to receive approval for biosimilar Pegfilgrastim from the U.S. FDA, ahead of a pack of strong competitors who are also
Page 11:  · worldwide. In June 2018, Biocon and Mylan became the first to receive approval for biosimilar Pegfilgrastim from the U.S. FDA, ahead of a pack of strong competitors who are also
Page 12:  · worldwide. In June 2018, Biocon and Mylan became the first to receive approval for biosimilar Pegfilgrastim from the U.S. FDA, ahead of a pack of strong competitors who are also